Disease: Acute Chest Syndrome ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 Biomarker disease BEFREE This research evaluated the frequency of variant alleles in the genes coding for CYP3A4, CYP3A5, CYP2C9, and CYP2C19 enzymes in patients on clopidogrel therapy and experiencing repeat acute coronary syndrome (ACS) compared to a control group with a matching ethnic composition. 19337788 2009
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE Homozygosity (A/A) for CYP2C19*2 mutant is an independent determinant of prognosis in patients with ACS. 21778720 2011
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE To investigate the prevalence and prognostic impact of the CYP2C19*2 allele in a local acute coronary syndrome (ACS) population. 22377481 2012
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE CYP2C19*2 allele and HPR by ADP are both independently associated with an increased risk of MACE in the first 6 months after ACS. 22390861 2012
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE A recent clinical trial has demonstrated that patients with acute coronary syndromes (ACS) and the reduced function allele CYP2C19*2 (*2 allele), who are treated with thienopyridines, have an increased risk of adverse cardiac events with clopidogrel, but not with prasugrel. 22974536 2012
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE The CYP2C19 genotype is a predictor of adverse cardiovascular events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) treated with clopidogrel. 23137413 2013
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 Biomarker disease BEFREE We sought to assess the relationships between platelet reactivity at different time points, CYP2C19*2 and ABCB1 status and clinical outcomes in patients with acute coronary syndromes (ACS). 23148794 2013
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE About three quarters of Japanese patients with ACS carried CYP2C19 variant alleles. 23886632 2013
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE Therefore, the present study was designed to investigate the impact of CYP2C19 loss-of-function point-of-care (POC) genotyping in patients presenting with acute coronary syndromes (ACS) and treated with dual antiplatelet therapy in the emergency setting. 24856643 2014
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE The study aims to examine the frequency of CYP2C19 variants and understand the factors associated with on-treatment platelet reactivity in a New Zealand ACS population. 25583161 2015
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE Seven studies including cost-effectiveness and risk-benefit analyses of CYP2C19 genotype-guided antiplatelet therapy in ACS patients were reviewed. 25660101 2015
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 Biomarker disease BEFREE Patients with poor and intermediate CYP2C19 metabolizers treated with clopidogrel incur higher cardiovascular event rates, including myocardial infarction, stroke, and stent thrombosis, following ACS than patients with normal CYP2C19 function. 26108379 2015
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 Biomarker disease BEFREE Although limited prospective trial data are available to support the utility of routine CYP2C19 testing, the increased risks for reduced clopidogrel efficacy among ACS/PCI patients that carry CYP2C19 loss-of-function alleles should be considered when genotype results are available. 26173871 2015
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE Genetic CYP2C19 polymorphisms are relative to the inferior, the antiplatelet activity after clopidogrel admission and may increase the incidence of ischemic events in patients with ACS. 26265611 2015
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 Biomarker disease BEFREE Our aim was to demonstrate that the sequential use of the Verigene® rapid CYP2C19 test for genetic profiling and the VerifyNowTM bedside test for platelet function measurement in ACS patients may optimise P2Y12 inhibition. 26423110 2016
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. 26521100 2016
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE This study sought to assess the effect of CYP2C19 genotype on ischemic outcomes in patients with ACS initially managed medically without revascularization who were randomized to either clopidogrel or prasugrel. 26916483 2016
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE This study further explored the relationship between CYP2C19 polymorphisms and clopidogrel resistance in ACS patients. 27323099 2016
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE Using both CYP2C19 GOF and LOF alleles to select antiplatelet therapy appears to be the preferred antiplatelet strategy over universal clopidogrel and universal alternative P2Y<sub>12</sub> inhibitor therapy for ACS patients with PCI. 27924429 2017
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE BACKGROUND The aim of this study was to observe the effects of genetic polymorphism of CYP2C19 on inhibitory effects of ticagrelor (Tic) and clopidogrel (Clo) towards post-percutaneous coronary intervention (PCI) platelet aggregation (IPA) and major cardiovascular events (MACE) in patients with acute coronary syndromes (ACS). 27977637 2016
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE This study aimed to evaluate the cost-effectiveness, from the Hong Kong health-care provider's perspective, of CYP2C19*2 genotype-guided selection of antiplatelet therapy compared with the universal use of clopidogrel or ticagrelor among ACS patients who undergo percutaneous coronary intervention (PCI). 28117433 2018
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 Biomarker disease BEFREE The aim of this study is to investigate the frequency of <i>CYP2C19*2, *3</i> allelic variants, associated with poor response to clopidogrel, and <i>CYP2C19*17</i>, associated with excessive response to clopidogrel, in patients with acute coronary syndrome (ACS) from Siberia and Moscow regions of Russia. 28442925 2017
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS. 28734158 2017
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 GeneticVariation disease BEFREE Seventy-six patients (median age 63, range 37-91 years) with an ACS who underwent PCI were screened for <i>CYP2C19</i> and <i>ABCB1</i> gene polymorphisms with real-time polymerase chain reaction: <i>CYP2C19*2</i>, <i>CYP2C19*17</i>, and <i>ABCB1 3435</i>. 29075133 2017
CUI: C0742343
Disease: Acute Chest Syndrome
Acute Chest Syndrome 		0.100 Biomarker disease BEFREE Genotyping of CYP2C19 and MACE of 934 ACS patients with PCI on clopidogrel maintenance therapy were analyzed. 29243114 2018